Abstract:
본 발명은 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 유효성분으로 포함하는 화장료 조성물을 제공한다. 본 발명의 펩타이드가 결합된 아스코르빈산 유도체는 멜라닌 생성 억제를 통한 미백 효과 및 콜라겐 생성 활성화를 통한 주름개선 효과를 동시에 나타내는 이중복합 기능을 가지며, 화장료 조성물에 사용될 수 있다.
Abstract:
The present invention relates to an antibody-linker-drug conjugate having an excellent anti-cancer activity, a preparation method thereof, and an anti-cancer agent composition containing the same as an active ingredient. In particular, in the antibody-linker-drug conjugate, the antibody and the cytotoxic drug are conjugated by the catalyst-decomposition type peptide linker, which can be directly bound to a lysine residue of the antibody.
Abstract:
The present invention relates to an antibody-linker-drug conjugate having an excellent anti-cancer activity, a preparation method thereof, and an anti-cancer agent composition containing the same as an active ingredient. In particular, in the antibody-linker-drug conjugate, the antibody and the cytotoxic drug are conjugated by the catalyst-decomposition type peptide linker, which can be directly bound to a lysine residue of the antibody.
Abstract:
The present invention relates to an antibody-linker-drug conjugate, a preparation method thereof, and an anti-cancer agent composition containing the same as an active ingredient. In particular, in the antibody-linker-drug conjugate, the antibody and the cytotoxic drug are conjugated by the catalyst-decomposition type peptide linker, which can be directly bound to a lysine residue of the antibody. The present invention relates to the antibody-linker-drug conjugate having an excellent anti-cancer activity, the preparation method thereof, and the anti-cancer agent composition containing the same as an active ingredient.
Abstract:
The present invention relates to an antibody-linker-drug conjugate having an excellent anti-cancer activity, a preparation method thereof, and an anti-cancer agent composition containing the same as an active ingredient. In particular, in the antibody-linker-drug conjugate, the antibody and the cytotoxic drug are conjugated by the catalyst-decomposition type peptide linker, which can be directly bound to a lysine residue of the antibody.